GDC-0339

GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma[1][2].

Product Specifications

CAS Number

[1428569-85-0]

UNSPSC

12352005

Target

Pim

Type

Reference compound

Related Pathways

JAK/STAT Signaling

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GDC-0339.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : ≥ 52 mg/mL

Smiles

FC1=CC=CC(F)=C1C2=NC(C(NC3=C(N4CC[C@@H](F)[C@H](N)CC4)N(C)N=C3)=O)=C(N)S2

Molecular Formula

C20H22F3N7OS

Molecular Weight

465.50

References & Citations

[1]Takahashi RH, et al. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metab Dispos. 2017 Oct;45 (10) :1084-1092.|[2]Wang X, et al. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem. 2019 Feb 28;62 (4) :2140-2153.